PTCT
PTC THERAPEUTICS, INC.
Nasdaq: PTCT · Warren, NJ · Healthcare
$76.82-1.63 (-2.08%)Closed
Market Cap$6.37B
Cash$1.89Bmost recent
Runway96 mo$59.0M Q burn
P/E (TTM)9.9EPS $7.78
52-Wk Range$43.30 – $89.55
Avg Volume1.5M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$76.82+128.8%
Pipeline

Drug candidates sponsored by PTC THERAPEUTICS · ClinicalTrials.gov

18 drugs · 64 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3Ataluren (PTC124®)
Cystic Fibrosis
Completed
2016-11past
1
Phase 3Deflazacort
Limb-Girdle Muscular Dystrophy+4 more
Completed
2021-07-31past
8
Phase 2PTC299
Pneumonia+7 more
Completed
2022-07-20past
5
Phase 2Unesbulin
Leiomyosarcoma
Completed
2024-06-17past
2
Phase 3Ataluren
Cystic Fibrosis+19 more
Completed
2026-02-10past
24
Phase 3PTC923
Phenylketonuria+2 more
Active, not recruiting
2026-06-30past
3
Phase 2Vatiquinone
Mitochondrial Diseases+10 more
Active, not recruiting
2027-12-31
6
Phase 3Sepiapterin
Phenylketonuria
Recruiting
2031-02-28
1
Phase 2PTC124
Cystic Fibrosis+1 more
Completed
2007-07past
3
Phase 2Placebo
Leigh Syndrome+1 more
Completed
2015-10-31past
2
Phase 2EPI-589
Amyotrophic Lateral Sclerosis
Completed
2018-02-23past
1
Phase 2CNSA-001
Gastroparesis
Completed
2019-09-08past
1
Phase 2Eladocagene Exuparvovec
AADC Deficiency
Active, not recruiting
2023-05-22past
1
Phase 2EPI-743
Leigh Syndrome+1 more
Completed
2023-10-30past
2
Phase 2PTC857
Amyotrophic Lateral Sclerosis
Terminated
2024-09-26past
1
Phase 1Deflazacort and rifampin
Healthy Volunteers
Completed
2014-12past
1
Phase 1PTC596
Cancer
Completed
2017-02-06past
1
N/AUnnamed
Muscular Dystrophy, Duchenne
Completed
2025-03-31past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for PTCT. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.